"Patients who experience hyperkalemia while on RAAS inhibitor therapy may benefit from intensification of other evidence-based preventative measures against adverse cardiorenal outcomes, such as lipid ...

WASHINGTON -- Use of the potassium-binding agent patiromer (Veltassa) allowed more heart failure patients at risk for hyperkalemia to remain on optimal therapy with renin-angiotensin-aldosterone ...

Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode ...

Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system inhibitor use in patients with hypertension and intracranial aneurysm was ...

Findings from the observational study indicate that the benefits of continuing RAAS inhibitor use outweigh the risks in patients with nondialysis chronic kidney disease. Patients with ...

Please provide your email address to receive an email when new articles are posted on . Fewer patients with hyperkalemia were prescribed renin-angiotensin-aldosterone system inhibitors for HF.

Uptitration of renin-angiotensin-aldosterone system (RAAS) inhibitors was less successful in women than men with acute heart failure (AHF), especially in those with HF with reduced ejection fraction.

A multi-center study of more than 3,000 people with high blood pressure and brain aneurysms found that the use of RAAS inhibitors, a class of blood pressure lowering medications, reduced the risk of ...

A woman reaching for a prescription bottle in a medicine cabinet Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone ...